BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24186319)

  • 21. RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib.
    Lilljebjörn H; Ågerstam H; Orsmark-Pietras C; Rissler M; Ehrencrona H; Nilsson L; Richter J; Fioretos T
    Leukemia; 2014 Apr; 28(4):977-9. PubMed ID: 24186003
    [No Abstract]   [Full Text] [Related]  

  • 22. Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.
    Ishibashi T; Yaguchi A; Terada K; Ueno-Yokohata H; Tomita O; Iijima K; Kobayashi K; Okita H; Fujimura J; Ohki K; Shimizu T; Kiyokawa N
    Exp Hematol; 2016 Mar; 44(3):177-88.e5. PubMed ID: 26703895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
    Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular framework for response to imatinib mesylate in systemic sclerosis.
    Chung L; Fiorentino DF; Benbarak MJ; Adler AS; Mariano MM; Paniagua RT; Milano A; Connolly MK; Ratiner BD; Wiskocil RL; Whitfield ML; Chang HY; Robinson WH
    Arthritis Rheum; 2009 Feb; 60(2):584-91. PubMed ID: 19180499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.
    Chalandon Y; Thomas X; Hayette S; Cayuela JM; Abbal C; Huguet F; Raffoux E; Leguay T; Rousselot P; Lepretre S; Escoffre-Barbe M; Maury S; Berthon C; Tavernier E; Lambert JF; Lafage-Pochitaloff M; Lhéritier V; Chevret S; Ifrah N; Dombret H;
    Blood; 2015 Jun; 125(24):3711-9. PubMed ID: 25878120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Outcome of autologous hematopoietic stem cell transplantation in combination with imatinib for 16 cases of Philadelphia chromosome positive acute lymphoblastic leukemia].
    Liu X; Jiang E; Huang Y; Yang D; Pang A; Wei J; Ma Q; Zhang R; Qiu L; Feng S; Han M
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):250-2. PubMed ID: 24666497
    [No Abstract]   [Full Text] [Related]  

  • 27. The
    Tran TH; Nguyen JV; Stecula A; Akutagawa J; Moorman AV; Braun BS; Sali A; Mullighan CG; Shah NP; Dai Y; Devidas M; Roberts KG; Smith CC; Loh ML
    Haematologica; 2021 Aug; 106(8):2242-2245. PubMed ID: 33626861
    [No Abstract]   [Full Text] [Related]  

  • 28. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
    Leoni V; Biondi A
    Haematologica; 2015 Mar; 100(3):295-9. PubMed ID: 25740105
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
    Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
    Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities.
    Ottmann OG; Hoelzer D
    Hematol J; 2002; 3(1):2-6. PubMed ID: 11960387
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.
    Koon HB; Krown SE; Lee JY; Honda K; Rapisuwon S; Wang Z; Aboulafia D; Reid EG; Rudek MA; Dezube BJ; Noy A
    J Clin Oncol; 2014 Feb; 32(5):402-8. PubMed ID: 24378417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta.
    Garcia JL; Font de Mora J; Hernandez JM; Queizan JA; Gutierrez NC; Hernandez JM; San Miguel JF
    Blood; 2003 Oct; 102(7):2699-700. PubMed ID: 14504072
    [No Abstract]   [Full Text] [Related]  

  • 33. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
    De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
    Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
    Walz C; Metzgeroth G; Haferlach C; Schmitt-Graeff A; Fabarius A; Hagen V; Prümmer O; Rauh S; Hehlmann R; Hochhaus A; Cross NC; Reiter A
    Haematologica; 2007 Feb; 92(2):163-9. PubMed ID: 17296564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Thomas X; Dombret H
    Leuk Lymphoma; 2008 Jul; 49(7):1246-54. PubMed ID: 18452076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
    Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
    Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
    Murphy M; Close J; Lottenberg R; Rajasekhar A
    Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
    [No Abstract]   [Full Text] [Related]  

  • 39. Kinase inhibitor therapy in CML: it's what's inside that counts.
    Eide CA; Druker BJ; O'Hare T
    Oncotarget; 2013 Sep; 4(9):1332-3. PubMed ID: 23934763
    [No Abstract]   [Full Text] [Related]  

  • 40. Possible alternative strategy for stage I imatinib-sensitive testicular seminoma; lessons from a case associated with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Okamura A; Wakahashi K; Ishii S; Katayama Y; Yamamoto K; Matsui T
    Ann Oncol; 2010 May; 21(5):1129-30. PubMed ID: 20080832
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.